Tauc3 Biologics

TauC3 Biologics is developing a disease-modifying treatment for tauopathies, including frontotemporal dementia due to tau pathology (FTD-tau) and progressive supranuclear palsy (PSP). Tauopathies are devastating and ultimately fatal neurodegenerative diseases typically manifesting as progressive dementia or movement impairment. Brain examination reveals abnormal deposits of tau protein that are believed to be preceded by toxic, soluble forms that lead to neuronal death. Currently in preclinical development, the company’s therapeutic candidate, TBL-100, is a humanized monoclonal antibody that uniquely targets a truncated form of tau known as tauC3 that appears to be highly elevated in these conditions. TauC3, is by far the most noxious form of tau due to its heightened propensity to aggregate, promote spread of tau pathology through the brain, and impair the delivery of mitochondria and other essential cellular constituents to synapses. TauC3’s ability to cause normal tau to aggregate confers enormous potential amplification causing extensive cellular damage. TBL-100 has specificity for tauC3 compared to normal tau and is believed to act at least in part by promoting clearance of tauC3 from the brain. In addition to its therapeutic potential, TBL-100’s specificity may enable use as a diagnostic agent for tauopathies, a critical tool that is currently lacking. Bringing together world-class expertise and drug development talent to turn its vision into a reality, TauC3 Biologics is poised for efficient preclinical development and subsequent early clinical development, with the aim of rapidly demonstrating safety and proof of concept.